Sands Capital

Portfolio Co Investors 2026 for Sands Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Sands Capital accounts for 18 tracked companies with verified cap-table data, 18 of which disclose round sizes totalling $6.9B. The median disclosed raise is $151M, and the largest is Rippling at $1.9B, ahead of Klaviyo ($1.5B) and OneTrust ($1.1B).

The names that recur most often on these co-invested cap tables are Sands Capital (18 companies), OrbiMed (2 companies), Lilly Asia Ventures (2 companies), Omega Funds (2 companies), RiverVest Venture Partners (2 companies), Khosla Ventures (2 companies). By latest disclosed round, the market skews Series B (5), Series C (4), Series A (3), Series D (2).

Best funded Sands Capital companies

  1. Rippling — $1.9B (latest: Series G)
  2. Klaviyo — $1.5B (latest: IPO)
  3. OneTrust — $1.1B (latest: Series C)
  4. Avenzo Therapeutics — $446M (latest: Series A)
  5. Beta Bionics — $333M (latest: Series E)
  6. Alamar Biosciences — $250M (latest: Series C)
  7. Wugen — $200M (latest: Series B)
  8. CytoVale — $180M (latest: Series D)
  9. Ancora Heart — $151M (latest: Series B)
  10. Nucleix — $143M (latest: Series C)
  11. Inspirna — $142M
  12. SafeBreach — $106M (latest: Series D)
  13. Earli — $104M (latest: Series A)
  14. Vitara Biomedical — $100M (latest: Series A)
  15. Spruce Biosciences — $88M (latest: Series B)

Sands Capital — related firms and companies (56)

Sands Capital profile · All research reports